- Home
- CRVS vs HRTX Comparison
CRVS vs HRTX Comparison
Compare CRVS & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- HRTX
- Stock Information
- Founded
- CRVS 2014
- HRTX 1983
- Country
- CRVS United States
- HRTX United States
- Employees
- CRVS N/A
- HRTX N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- HRTX Health Care
- Exchange
- CRVS Nasdaq
- HRTX Nasdaq
- Market Cap
- CRVS 305.4M
- HRTX 276.1M
- IPO Year
- CRVS 2016
- HRTX 1987
- Fundamental
- Price
- CRVS $5.75
- HRTX $1.35
- Analyst Decision
- CRVS Strong Buy
- HRTX Strong Buy
- Analyst Count
- CRVS 4
- HRTX 2
- Target Price
- CRVS $15.00
- HRTX $4.50
- AVG Volume (30 Days)
- CRVS 518.7K
- HRTX 2.6M
- Earning Date
- CRVS 08-07-2025
- HRTX 08-08-2025
- Dividend Yield
- CRVS N/A
- HRTX N/A
- EPS Growth
- CRVS N/A
- HRTX N/A
- EPS
- CRVS N/A
- HRTX N/A
- Revenue
- CRVS N/A
- HRTX $149,694,000.00
- Revenue This Year
- CRVS N/A
- HRTX $10.62
- Revenue Next Year
- CRVS N/A
- HRTX $12.99
- P/E Ratio
- CRVS N/A
- HRTX N/A
- Revenue Growth
- CRVS N/A
- HRTX 9.78
- 52 Week Low
- CRVS $2.54
- HRTX $1.04
- 52 Week High
- CRVS $10.00
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- HRTX 36.48
- Support Level
- CRVS $5.28
- HRTX $1.33
- Resistance Level
- CRVS $5.64
- HRTX $1.43
- Average True Range (ATR)
- CRVS 0.30
- HRTX 0.07
- MACD
- CRVS 0.03
- HRTX 0.02
- Stochastic Oscillator
- CRVS 77.70
- HRTX 45.45
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.